File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3748/wjg.14.6437
- Scopus: eid_2-s2.0-63449111025
- PMID: 19030192
- WOS: WOS:000261227200001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Evolution of systemic therapy of advanced hepatocellular carcinoma
Title | Evolution of systemic therapy of advanced hepatocellular carcinoma |
---|---|
Authors | |
Keywords | Advanced hepatocellular carcinoma Chemotherapy Doxorubicin Sorafenib |
Issue Date | 2008 |
Publisher | Baishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htm |
Citation | World Journal Of Gastroenterology, 2008, v. 14 n. 42, p. 6437-6441 How to Cite? |
Abstract | Hepatocellular carcinoma (HCC) commonly occurs in hepatitis B endemic areas, especially in Asian countries. HCC is highly refractory to cytotoxic chemotherapy. This resistance is partly related to its tumor biology, pharmacokinetic properties, and both intrinsic and acquired drug resistance. There is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients. Other systemic approaches, such as hormonal therapy and immunotherapy, have also disappointing results. Recently, encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients. In this review, we concisely summarize the evolution of developments in the systemic therapy of advanced HCC. © 2008 The WJG Press. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/59192 |
ISSN | 2023 Impact Factor: 4.3 2023 SCImago Journal Rankings: 1.063 |
PubMed Central ID | |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yau, T | en_HK |
dc.contributor.author | Chan, P | en_HK |
dc.contributor.author | Epstein, R | en_HK |
dc.contributor.author | Poon, RT | en_HK |
dc.date.accessioned | 2010-05-31T03:44:46Z | - |
dc.date.available | 2010-05-31T03:44:46Z | - |
dc.date.issued | 2008 | en_HK |
dc.identifier.citation | World Journal Of Gastroenterology, 2008, v. 14 n. 42, p. 6437-6441 | en_HK |
dc.identifier.issn | 1007-9327 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/59192 | - |
dc.description.abstract | Hepatocellular carcinoma (HCC) commonly occurs in hepatitis B endemic areas, especially in Asian countries. HCC is highly refractory to cytotoxic chemotherapy. This resistance is partly related to its tumor biology, pharmacokinetic properties, and both intrinsic and acquired drug resistance. There is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients. Other systemic approaches, such as hormonal therapy and immunotherapy, have also disappointing results. Recently, encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients. In this review, we concisely summarize the evolution of developments in the systemic therapy of advanced HCC. © 2008 The WJG Press. All rights reserved. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Baishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htm | en_HK |
dc.relation.ispartof | World Journal of Gastroenterology | en_HK |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Advanced hepatocellular carcinoma | en_HK |
dc.subject | Chemotherapy | en_HK |
dc.subject | Doxorubicin | en_HK |
dc.subject | Sorafenib | en_HK |
dc.subject.mesh | Antineoplastic Agents - therapeutic use | - |
dc.subject.mesh | Carcinoma, Hepatocellular - drug therapy - mortality - pathology | - |
dc.subject.mesh | Immunologic Factors - therapeutic use | - |
dc.subject.mesh | Liver Neoplasms - drug therapy - pathology | - |
dc.subject.mesh | Thalidomide - therapeutic use | - |
dc.title | Evolution of systemic therapy of advanced hepatocellular carcinoma | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Yau, T: tyaucc@hku.hk | en_HK |
dc.identifier.email | Epstein, R: repstein@hku.hk | en_HK |
dc.identifier.email | Poon, RT: poontp@hku.hk | en_HK |
dc.identifier.authority | Yau, T=rp01466 | en_HK |
dc.identifier.authority | Epstein, R=rp00501 | en_HK |
dc.identifier.authority | Poon, RT=rp00446 | en_HK |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3748/wjg.14.6437 | en_HK |
dc.identifier.pmid | 19030192 | - |
dc.identifier.pmcid | PMC2773326 | - |
dc.identifier.scopus | eid_2-s2.0-63449111025 | en_HK |
dc.identifier.hkuros | 167035 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-63449111025&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 14 | en_HK |
dc.identifier.issue | 42 | en_HK |
dc.identifier.spage | 6437 | en_HK |
dc.identifier.epage | 6441 | en_HK |
dc.identifier.isi | WOS:000261227200001 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Yau, T=23391533100 | en_HK |
dc.identifier.scopusauthorid | Chan, P=7403497715 | en_HK |
dc.identifier.scopusauthorid | Epstein, R=34975074500 | en_HK |
dc.identifier.scopusauthorid | Poon, RT=7103097223 | en_HK |
dc.identifier.issnl | 1007-9327 | - |